JMP Securities Upgrades Myriad Genetics (MYGN) to Market Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/4/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Jefferies Stays on Sidelines with Myriad (MYGN) after DNA Ruling
June 14, 2013 7:57 AM EDTJefferies reiterated a Hold rating and $31 price target on Myriad Genetics (NASDAQ: MYGN) Friday following yesterday's US Supreme Court ruling that the company's human isolated DNA patent claims are invalid, while its synthetic DNA (cDNA) claims are patent eligible.
"While the court's... More
BofA/Merrill Lynch Downgrades Myriad Genetics (MYGN) to Neutral
June 14, 2013 6:46 AM EDTBofA/Merrill Lynch downgraded Myriad Genetics (NASDAQ: MYGN) from Buy to Neutral.
For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.
Shares of Myriad Genetics closed at $32.01 yesterday, with a 52 week range of $22.02-$38.27.... More
RBC Capital Downgrades Myriad Genetics (MYGN) to Sector Perform
June 14, 2013 6:45 AM EDTRBC Capital downgraded Myriad Genetics (NASDAQ: MYGN) from Outperform to Sector Perform with a price target of $32.00 (unchanged).
For an analyst ratings summary and ratings history on Myriad Genetics click here. For... More
Leerink Swann Downgrades Myriad Genetics (MYGN) to Market Perform
June 13, 2013 2:44 PM EDTLeerink Swann downgraded Myriad Genetics (NASDAQ: MYGN) from Outperform to Market Perform with a price target of $39.00. Analyst Dan Leonard thinks investor focus will now turn to competition and the stock has no place to go but down.
"Following the Supreme Court's... More
Piper Jaffray Boosts Myriad Genetics (MYGN) Price Target to $49
June 13, 2013 1:50 PM EDTPiper Jaffray today maintained an Overweight rating on Myriad Genetics (NASDAQ: MYGN) and raised its price target to a Street-high $49.00 (from $39.00).
For an analyst ratings summary and ratings history on Myriad Genetics click... More
Myriad (MYGN) Issues Response to Supreme Court Decision on Gene Patent
June 13, 2013 10:55 AM EDTMyriad Genetics (Nasdaq: MYGN) posted the following response to the U.S. Supreme Court ruling made earlier on its Facebook page:
"The Supreme Court has... More
Myriad Genetics (MYGN) trading paused/halted due to limit up, limit down
June 13, 2013 10:26 AM EDTMyriad Genetics, Inc. (NASDAQ: MYGN) trading paused due to limit up, limit down.... More
Gene Patent Limited by High Court in Mixed Ruling for Myriad (MYGN)
June 13, 2013 10:24 AM EDT(Updated - June 13, 2013 10:33 AM EDT)
Gene patent limited by high court in mixed ruling for Myriad Genetics, Inc. (NASDAQ: MYGN), according to Bloomberg headlines.
For the U.S. Supreme Court document (pdf format), click here.
Myriad is up 9 percent on the session.... More
